Copyright
©The Author(s) 2016.
World J Gastroenterol. Jan 7, 2016; 22(1): 253-261
Published online Jan 7, 2016. doi: 10.3748/wjg.v22.i1.253
Published online Jan 7, 2016. doi: 10.3748/wjg.v22.i1.253
Table 1 Clinical trials of immune therapy in hepatocellular carcinoma
| Regimen | Patients, n | Clinical response | Reference |
| HCC vaccines | |||
| DC's + auto-tumor lysate | 31 | PR: 12.9%, SD: 54.8% | Lee et al[53], 2005 |
| DC's + 4 AFP peptides | 16 | No clinical response | Butterfield et al[30], 2007 |
| DC's + HepG2 lysate | 25 | PR + SD: 28% | Palmer et al[52], 2009 |
| GV 1001 + GM-CSF | 40 | SD: 45.9% | Greten et al[71], 2010 |
| GPC3 peptides | 33 | PR: 3%, SD: 57.6% | Sawada et al[72], 2012 |
| DC's | 30 | PR: 17%, SD: 60% | El Ansary et al[49], 2013 |
| Immune checkpoint inhibitors | |||
| Tremelimumab | 21 | PR: 17.6%, SD: 58.8% | Sangro et al[62], 2013 |
- Citation: Aerts M, Benteyn D, Van Vlierberghe H, Thielemans K, Reynaert H. Current status and perspectives of immune-based therapies for hepatocellular carcinoma. World J Gastroenterol 2016; 22(1): 253-261
- URL: https://www.wjgnet.com/1007-9327/full/v22/i1/253.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i1.253